...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer
【24h】

Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer

机译：与纳米紫杉醇加上吉西他滨的联合治疗与复发性胰腺癌患者的可行性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Nab-paclitaxel plus gemcitabine (nab-P+Gem) is one of most reliable and effective regimens for borderline or unresectable pancreatic cancer (PC). However, the feasibility and clinical benefits of this regimen have never been evaluated for patients with recurrent PC after pancreatectomy. The aim of this study was to investigate the feasibility of combination therapy with nab-paclitaxel plus gemcitabine (nab-P+Gem) for patients with recurrent PC. Patients and Methods: Twenty-two patients with recurrent PC received an intravenous infusion of nab-P (125 mg/m(2)) and Gem (1,000 mg/m(2)) on days 1, 8, and 15 of a 4-week cycle. The primary end-point of this study was completion of the 4 cycles. The secondary end-points were the safety, efficacy, and disease control rate. Results: The treatment completion rate of the 4 cycles was 90.9%. The objective response rate was 13.6% and the disease control rate was 63.6%. The median progression free survival was 7.2 months. The most common grade 3 or higher hematological toxicity was neutropenia (72.7%). There was no treatment-related death. Furthermore, the chemotherapeutic effects varied with the time of recurrence. Conclusion: Combination nab-P+Gem therapy was well-tolerated and effective in patients with recurrent PC.
机译：背景/目的：Nab-Paclitaxel Plus Gemcitabine（Nab-P + Gem）是边界或不可切征的胰腺癌（PC）中最可靠和最有效的方案之一。然而，这种方案的可行性和临床效益从未评估了胰腺切除术后经常性PC的患者。本研究的目的是探讨与患有复发PC患者的Nab-Paclitaxel Plus Gemcitabine（Nab-P + Gem）的联合治疗的可行性。患者及方法：二十二名经常性PC患者接受静脉注射Nab-P（125mg / m（2））和1,8和4天的1,8和15天）（1,000mg / m（2）） - 周周期。本研究的主要终点是完成4个循环。次要终点是安全性，疗效和疾病控制率。结果：4个循环的治疗完成率为90.9％。目标反应率为13.6％，疾病控制率为63.6％。中位进展免费生存率为7.2个月。最常见的3级或更高的血液毒性是中性粒细胞症（72.7％）。没有治疗相关的死亡。此外，化学治疗效果随着复发时间而变化。结论：结合Nab-P + Gem疗法在经常性PC的患者中耐受良好耐受性和有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号